Could a drug revive immune systems in the ICU?
NCT ID NCT06694740
First seen Nov 19, 2025 · Last updated Jun 16, 2026 · Updated 30 times
Summary
This study tests whether a drug called interferon gamma can help intensive care patients whose immune systems have shut down after a severe injury or infection. The main goal is to see if it helps them spend more days alive and off a breathing machine. About 170 adults on ventilators with low immune markers will receive either the drug or a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-AGGRESSIVE IMMUNOSUPPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr de Roquetaillade
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Pr Dépret
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.